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SUMMARY: Method: Eighty patients were prospectively randomized for precolonoscopic cleansing either with 750 ml of 10% mannitol (Group
M) or 180 ml of a sodium phosphate preparation (Group NaP). Laboratory examinations before and after preparation on all patients included hemoglobin,
hematocrit, sodium, potassium, phosphorous, calcium and serum osmolarity. A questionnaire was used to assess undesirable side effects and patient
tolerance to the solution. The quality of preparation was assessed by the endoscopist who was unaware of the solution employed.
Results: Statistically significant changes were verified in serum sodium, phosphorous, potassium and calcium between the two groups, but no
clinical symptoms were observed. There were no significant differences in the frequency of side effects studied. Six of the eight patients in Group NaP
who had taken mannitol for a previous colonoscopy claimed better acceptance of the sodium phosphate solution. The endoscopic-blinded trial reported
excellent or good bowel preparation in 85% prepared with sodium phosphate versus 82.5% for mannitol (p=0.37).
Conclusions: Quality of preparation and frequency of side effects was similar in the two solutions. The smaller volume of sodium phosphate
necessary for preparation seems to be related to its favorable acceptance. Nevertheless, the retention of sodium and phosphate ions contraindicates the
use of sodium phosphate in patients with renal failure, cirrhosis, ascites, and heart failure.
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The ideal method of bowel prepa-
ration for colonoscopy associates effec-
tiveness, safety, ease of administration,
low cost, and good patient acceptance.
Mannitol (M) and polyethyleneglycol
(PEG) are the most commonly utilized,
with various articles confirming that
both are equally effective and safe for
bowel cleansing1,6. Nevertheless, about
5–15% of patients experience difficulty
in swallowing the necessary volume,
especially when using PEG, resulting
in inadequate bowel preparation7,8. Use
of sodium phosphate is an attempt to
improve tolerance, since a considerably
smaller volume is required, maintain-
ing the same effectiveness9,15. We con-
firmed these findings for sodium phos-
phate compared to PEG in a random-
ized prospective study on 90 patients
undergoing elective colorectal sur-
gery16 encouraging us to also utilize
sodium phosphate for precolonoscopic
cleansing.
The purpose of the present random-
ized, prospective study is to compare
precolonscopic preparation with man-
nitol and sodium phosphate, analyzing
for their effectiveness, safety, and side
effects.
PATIENTS AND METHOD
The study was prospective and in-
cluded 80 patients undergoing elective
colonoscopy in the Colonoscopy Unit
of the Coloproctology Division of Hos-
pital das Clinicas, University of São
Paulo during the period from April to
July 1998. Only patients with a diag-
nosis of renal failure, liver disease with
ascites, and severe congestive heart
failure, and those undergoing emer-
gency colonoscopies were excluded
from this investigation. After an expla-
nation about the study, all patients
signed a consent agreement.
The patients were randomized by
simple heads-or-tails allotment and
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were given 10% mannitol (Group M)
or sodium phosphate (Group NaP) for
bowel preparation. Both solutions are
currently produced at our pharmacy.
Patients were instructed to follow a liq-
uid diet without residues, starting after
lunch on the day prior to the examina-
tion. Subjects in Group M were also
instructed to take four tablets of
bisacodyl (Dulcolax®, Boehringer De
Angeli, São Paulo, SP) on the night
prior to the exam. They were admitted
on the morning of the colonoscopy and
received two ml of metoclopramide in-
tramuscularly prior to drinking 750 ml
of 10% mannitol21. The sodium phos-
phate solution (monobasic sodium
phosphate: 0.24 g/ml and dibasic so-
dium phosphate: 0.09 g/ml) was ad-
ministered in two equal doses of 90 ml.
The first dose on the afternoon prior to
the examination (16:00h) and the sec-
ond on the morning of the colonoscopy
(07:00h), for a total of 180 ml. The
colonoscopies were performed in the
late morning.
The following data were recorded:
sex, age, and variation of body weight
(patients were weighed immediately
before bowel prep and right after ex-
amination). Laboratory tests (hemoglo-
bin level and hematocrit, serum Na, se-
rum K, serum P, serum Ca, and serum
osmolarity) were performed in all, im-
mediately before and after bowel
cleansing. Upon completion of bowel
preparation and before colonoscopy,
patients filled out a questionnaire with
the objective of identifying side effects
(nausea, vomiting, abdominal pain, ab-
dominal distension, dizziness, perianal
irritation) and degree of acceptance of
the solution given.
Bowel preparation was evaluated
by the endoscopist in a blinded-trial
and graded as:
• Excellent – presence of clear fluid,
without any fecal material
• Good – presence of cloudy fluid,
but without residues.
• Poor – presence of residues.
The endoscopic diagnosis and com-
plications were also recorded. Statisti-
cal analysis was based on Fisher and
chi-square tests, with values of p < 0.05
considered statistically significant.
Forty of the 80 patients in the study
received 10% mannitol for bowel prepa-
ration and the other 40 received sodium
phosphate. Table 1 displays the data of
the two groups. No statistically signifi-
cant difference was noted regarding
gender or age between the groups.
RESULTS
The biochemical analysis demon-
strated a significant rise in serum so-
dium and phosphorous and a marked
drop in potassium and calcium in
Figure 1 - Graphs, illustrating weight and laboratory examinations.
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Group NaP compared to Group M (p
= 0.0001). Nevertheless, there were no
clinical symptoms. A slight increase
occurred in hemoglobin (p=0.16), he-
matocrit (p=0.36), and serum osmolar-
ity (p=0.74) in both groups, but these
were without statistical significance.
Weight loss (kg) in both groups was
similar, 0.80 ± 1.4 for the Group NaP
and 1.1 ± 1.2 for the Group M, with-
out a statistically significant difference
between them (p=0.42). Figure 1 illus-
trates weight variations and laboratory
parameters between the two groups.
Bowel preparation was judged ex-
cellent or good in 85% of cases pre-
pared with sodium phosphate and in
82.5% prepared with mannitol (p=0.37).
A poor preparation was obtained in
15% and 17.5% in Group NaP and
Group M respectively. In three patients
who had been prepared with mannitol,
it was impossible to complete the
colonoscopy because of poor bowel
cleansing. Table 2 displays patient dis-
tribution based on quality of bowel
preparation and solution utilized.
Nausea and vomiting were the most
frequent undesirable effects reported by
patients of both groups. They occurred
in 50% and 18% of those taking sodium
phosphate and in 30% and 18% in those
taking mannitol, respectively. Eight pa-
tients receiving sodium phosphate had
been prepared for a previous colo-
noscopy with mannitol, and six of them
claimed better acceptance of sodium
phosphate. The Fisher test did not dem-
onstrate a significant difference between
the two groups for these variables (nau-
sea, p = 0.11; vomiting, p = 1.00).
Distribution of endoscopic findings
according to the type of the solution is
displayed in Table 3. There was no sta-
tistically significant difference between
the two groups (p > 0.01).
DISCUSSION
The success of colonoscopy is di-
rectly related to the degree of bowel
cleansing since it is based on perfect vi-
sualization of the colorectal mucosa.
Thus, with improper cleansing, small le-
sions can be obscured by fecal residues
in the lumen, impairing detection and
treatment of various colonic diseases.
The ideal method for precolo-
noscopy preparation should be effec-
tive, safe, easily administered, and well
tolerated by the patient. Anterograde
methods fulfill these requirements and
have gradually replaced the conven-
tional method, based on diet, laxatives,
and enemas. Mannitol and polyethy-
leneglycol (PEG) are currently the
most commonly utilized oral solutions,
each with inherent advantages and dis-
advantages1–6. Both solutions accom-
plish adequate colonic cleansing when
properly administered.
The monosaccharide mannitol so-
lution is almost non-absorbable in con-
centrations ranging from 5–20% and
volumes of 500 to 750 ml. Its effect is
due to the promotion of osmotic diar-
rhea with practically no absorption of
water. Various studies have confirmed
the effectiveness and safety of this so-
lution for colonoscopic preparation and
have achieved excellent or good results
in over 90% of cases1,2. Because of the
risk of explosion during electrocauter-
ization resulting from fermentation of
mannitol by hydrogen- and methane-
producing intestinal bacteria, its use
has been criticized and restricted in
various centers in the United States and
Europe17–19.
PEG preparations eliminate risk of
explosion and are osmotically neutral,
thus reducing the possibility of promot-
Table 3 - Distribution of endoscopic findings in the two groups.
Diagnosis NaP M
Normal 20 (50%) 18 (46%)
Polyp 6 (15%) 6 (15%)
Colorectal neoplasm 3 (7.5%) 5 (12%)
UC 5 (12.5%) 3 (7.5%)
Diverticular disease 4 (10%) 2 (5%)
Crohn’s disease 0 (0%) 1 (2.5%)
Vascular ectasia 0 (0%) 1 (2.5%)
Others 2 (5%) 4 (10.%)
Total 40 (100%) 40 (100%)
Table 2 - Quality of bowel preparation and group studied.
Quality of preparation  NaP  M  Total
Excellent 23 (57.5%) 26 (65.%) 49 (61.2%)
Good 11 (27.5%)  7 (17.5%) 18 (22.5%)
Poor 6 (15%) 7 (17.5%) 13 (16.3%)
Total 40 (100%) 40 (100%) 80 (100%)
Table 1 - Gender and age distribution in the two groups.
Total Mannitol NaP p
N (%) 80 (100%) 40 (50%) 40 (50%)
Males 43 (54%) 22 (55%) 21 (52%)
1.00
Mean age 56.0 ± 16.3 56.0 ± 14.9 56.1 ± 12.9
1.00
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ing significant changes in fluids or
electrolytes. For a proper cleansing, of
a greater volume of PEG than manni-
tol must be ingested (about four liters).
Drinking large volumes of liquids re-
sults in unacceptable bowel preparation
in about 5–15% of patients, especially
those with pharyngeal reflex problems,
such as the elderly or those who have
had strokes or neurological distur-
bances7-8, and children14.
The present study was motivated by
the good results obtained with the so-
dium phosphate solution for mechani-
cal bowel preparation for elective
colorectal surgery presented in the lit-
erature21 and by our own experience16
confirming better acceptance of so-
dium phosphate, especially because of
the small volume utilized for colonos-
copic bowel preparation. Some re-
searchers have also demonstrated the
advantages of sodium phosphate solu-
tion, especially comparing its use with
the PEG solution9–15.
In the present study, we compared
the use of sodium phosphate and 10%
mannitol, since the latter has been our
method of choice for bowel prepara-
tion for colonoscopy for many years.
We were not able to find a report of a
similar investigation comparing sodium
phosphate and mannitol, probably be-
cause of the preference for PEG in the
majority of American and European
medical centers.
The number of side effects was
similar in the two groups, especially
regarding nausea and vomiting. De-
spite more frequent bouts of nausea
(50% vs. 30%) in the sodium phos-
phate group, the incidence of vomiting
was identical in both groups (18%).
Probably, the routine use of meto-
clopramide in patients receiving man-
nitol contributed to their lower inci-
dence of nausea. In the literature, the
incidence of nausea and vomiting re-
sulting from sodium phosphate ranges
from 11.2 to 44.3% and 5.4 to 8.6%,
respectively11,10,15. Frommer15 compared
sodium phosphate and PEG in 486 pa-
tients submitted to colonoscopy and
found a greater incidence of minor side
effects, such as, nausea and vomiting
in patients prepared with sodium phos-
phate. However, the majority of articles
comparing the two solutions (PEG x
NaP) mention a lower incidence of side
effects with sodium phosphate 9–14,16.
The acceptance of ingesting one
solution versus the other is difficult to
compare, since acceptance is a subjec-
tive variable, perhaps reliably reported
only by patients who have taken both
solutions. In the present study, eight
patients in the sodium phosphate group
had been prepared with mannitol for
previous examination, and six of them
indicated better acceptance of sodium
phosphate. The other two did not per-
ceive a difference. Vanner et al.9
deemed sodium phosphate more easily
acceptable than PEG in a prospective
study including 102 patients, and 37 of
them who had been previously pre-
pared with PEG stated their preference
for sodium phosphate. Other reports
have demonstrated that there is no sig-
nificant clinical difference in the inci-
dence and intensity of side effects, but
that swallowing a smaller volume of
sodium phosphate solution compared
to PEG is more easily accepted10–14.
Hyperphosphatemia and hypocal-
cemia were the most common labora-
tory changes found in the sodium
phosphate group, but there were no de-
tectable clinical symptoms. Various ar-
ticles have mentioned temporary
hyperphosphatemia after the use of so-
dium phosphate 9–12,15. Although there
are no reports of clinical problems due
to increased serum levels of phosphate
in normal adults, sodium phosphate
should be avoided in patients with re-
nal diseases9,11,16. There was also
greater retention of sodium ions, and
greater loss of potassium in patients
taking sodium phosphate, but without
associated clinical symptoms in any of
the cases. Nevertheless, this data
obliges us to issue a warning restrict-
ing the use of sodium phosphate in pa-
tients with congestive heart failure or
cirrhosis with ascitis.
Concerning the quality of bowel
preparation, both solutions obtained
similar results, with excellent or good
in 85% and 82.5% respectively for so-
dium phosphate and mannitol. Our
data is similar to those obtained in
other investigations studying the effec-
tiveness of sodium phosphate for
colonoscopy9-15. Some researchers con-
sider sodium phosphate more effective
than PEG for bowel cleansing, justify-
ing these results on the basis of the
greater acceptance of sodium phos-
phate, which requires a markedly
smaller volume than PEG9,11,13,14. The
examination was discontinued in three
patients taking mannitol due to inad-
equate cleansing, because of vomiting
in two of them.
The use of sodium phosphate has
been associated with coarse macro-
scopic changes in the bowel mucosa20.
These changes range from friability and
hyperemia to aphthoid injuries. How-
ever, we did not note these changes in
any patient in the present study.
Based on the results of this series,
we conclude that bowel preparation for
elective colonoscopy may be equally
effective and safe with either mannitol
10% or sodium phosphate solutions.
However, due to the smaller volume
necessary for adequate bowel cleans-
ing, sodium phosphate seems to be bet-
ter tolerated than mannitol. This is es-
pecially important in patients with dif-
ficulty in swallowing large volumes.
Perhaps routine administration of an
oral or parenteral antiemetic can fur-
ther improve acceptance of sodium
phosphate. However, retention of phos-
phate and sodium ions in patients with
renal problems, liver diseases with as-
cites, and those with congestive heart
failure makes the use of sodium phos-
phate solution inadvisable in patients
with these complications.
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RESUMO RHCFAP/2990
HABR-GAMA A e col. - Preparo in-
testinal para colonoscopia: manitol
vs fosfato de sódio. Resultados de
estudo prospectivo e randomizado.
Rev Hosp Clín Fac Med S Paulo
54 (6):187-192, 1999.
Métodos: Oitenta pacientes foram
prospectivamente randomizados para
receber 750 ml de manitol a 10% (M)
ou 180 ml de solução à base de fosfato
de sódio (FS), como preparo intestinal
para colonoscopia eletiva. Todos os pa-
cientes foram submetidos a avaliação
laboratorial (hemoglobina, hemató-
crito, sódio, potássio, fósforo, cálcio e
osmolaridade sérica) antes e depois do
preparo. Completado o preparo intes-
tinal, antes da realização do exame, os
pacientes foram avaliados por questi-
onário com a finalidade de identificar
efeitos indesejáveis e tolerabilidade
inerentes à solução empregada. A qua-
lidade do preparo foi avaliada pelo
colonoscopista, que desconhecia o tipo
de solução empregada.
Resultados: A análise bioquímica
demonstrou elevação significativa dos
níveis séricos de sódio e fósforo no
grupo do FS, bem como uma queda
mais acentuada do pótassio e cálcio
séricos neste grupo, mas nenhuma des-
tas alterações foi clinicamente sintomá-
tica. Não houve diferença significante
na incidência de seis efeitos colaterais
pesquisados. Seis de oito pacientes do
grupo FS que em exame colonóscopico
anterior haviam recebido manitol, ma-
nifestaram melhor tolerabilidade com
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